Baird raised the firm’s price target on Axsome Therapeutics (AXSM) to $116 from $112 and keeps an Outperform rating on the shares. The firm said 3Q24 was a strong quarter, primarily due to an encouraging uptick in Auvelity sales. The company continues to be one of the firm’s top picks, because they believe the stock has the most attractive set of catalysts between now and the end of 4Q24 in their coverage universe.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics’ Strong Q3 Growth Amidst Strategic Expansions
- Axsome Therapeutics reports Q3 EPS ($1.34), consensus ($1.41)
- Axsome Therapeutics expects cash to fund operations into cash flow positivity
- AXSM Earnings this Week: How Will it Perform?
- Axsome Therapeutics added to Q4 2024 Tactical Ideas List at Wells Fargo